Publication:
Distinguishing reference intervals and clinical decision limits – A review by the IFCC committee on reference intervals and decision limits

dc.contributor.authorSikaris, Ken Andrew
dc.contributor.authorStreichert, Thomas
dc.contributor.authorMacri, Joseph
dc.contributor.buuauthorİlçöl, Yeşim Özarda
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıbbı Biyokimya Ana Bilim Dalı
dc.contributor.researcheridAAL-8873-2021
dc.contributor.scopusid35741320500
dc.date.accessioned2022-12-21T12:13:49Z
dc.date.available2022-12-21T12:13:49Z
dc.date.issued2018-05-18
dc.description.abstractReference Intervals (RIs) and clinical decision limits (CDLs) are a vital part of the information supplied by laboratories to support the interpretation of numerical clinical pathology results. RIs describe the typical distribution of results seen in a healthy reference population while CDLs are associated with a significantly higher risk of adverse clinical outcomes or are diagnostic for the presence of a specific disease. However, as the two concepts are sometimes confused, there is a need to clarify the differences between these terms and to ensure they are easily distinguished, especially because CDLs have a clinical association with specific diseases and risks, thereby implying that effective clinical interventions are available. It is important to note that, because population-based RIs are derived from the range of values expected in a typical community population, laboratory results that fall outside a RI do not necessarily indicate a disease but rather that additional medical follow-up and/or treatment may be warranted. In contrast, CDLs are associated with a risk of specific adverse outcomes, and are commonly used to interpret laboratory test results, including lipid parameters, glucose, hemoglobin A1c (HbA1c), and tumor markers, to determine risk of disease, to diagnose or to treat. In recent years, the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Committee on Reference Intervals and Decision Limits (C-RIDL) has focused primarily on RIs and has performed multicenter studies to obtain common RIs. However, the broader responsibility of the Committee, from its name, includes decision limits. C-RIDL now aims to emphasize the importance of the correct use of both RIs and CDLs and to encourage laboratories to specify the appropriate information to clinicians as needed. This review discusses RIs and CDLs in detail, describes the similarities and the differences between these two important tools in laboratory medicine, and clearly explains the processes used to define them. C-RIDL encourages the involvement of laboratory professionals in the establishment of both RIs and CDLs.
dc.identifier.citationÖzarda, Y. vd. (2018). ''Distinguishing reference intervals and clinical decision limits – A review by the IFCC committee on reference intervals and decision limits''. Critical Reviews in Clinical Laboratory Sciences, 55(6), 420-431.
dc.identifier.endpage431
dc.identifier.issn1040-8363
dc.identifier.issn1549-781X
dc.identifier.issue6
dc.identifier.pubmed30047297
dc.identifier.scopus2-s2.0-85051077162
dc.identifier.startpage420
dc.identifier.urihttps://doi.org/10.1080/10408363.2018.1482256
dc.identifier.urihttps://www.tandfonline.com/doi/full/10.1080/10408363.2018.1482256
dc.identifier.urihttp://hdl.handle.net/11452/30010
dc.identifier.volume55
dc.identifier.wos000440701500003
dc.indexed.scopusScopus
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherTaylor and Francis
dc.relation.collaborationYurt dışı
dc.relation.collaborationSanayi
dc.relation.journalCritical Reviews in Clinical Laboratory Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectReference intervals
dc.subjectClinical decision limits
dc.subjectC-RIDL
dc.subjectClinical laboratories
dc.subjectProstate-specific antigen
dc.subjectEuropean atherosclerosis society
dc.subjectPrediatric peference intervals
dc.subjectApproved recommendation1987
dc.subjectJoint consensus statement
dc.subjectHigh-density-lipoprotein
dc.subjectReference values
dc.subject99th percentile
dc.subjectAnalytical performance
dc.subjectGlobal multicenter
dc.subjectMedical laboratory technology
dc.subject.emtreeGlucose
dc.subject.emtreeHemoglobin A1c
dc.subject.emtreeLipid
dc.subject.emtreeClinical decision limit
dc.subject.emtreeClinical decision making
dc.subject.emtreeHealth care organization
dc.subject.emtreeHuman
dc.subject.emtreeLaboratory test
dc.subject.emtreePriority journal
dc.subject.emtreeReference value
dc.subject.emtreeReview
dc.subject.emtreeLaboratory
dc.subject.emtreeLaboratory technique
dc.subject.emtreeOrganization and management
dc.subject.emtreeStandards
dc.subject.meshClinical laboratory techniques
dc.subject.meshHumans
dc.subject.meshLaboratories
dc.subject.meshReference values
dc.subject.scopusClinical Chemistry; Thyrotropin; Chemical Species
dc.subject.wosMedical laboratory technology
dc.titleDistinguishing reference intervals and clinical decision limits – A review by the IFCC committee on reference intervals and decision limits
dc.typeReview
dc.wos.quartileQ1
dc.wos.quartileQ1
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Tıbbı Biyokimya Ana Bilim Dalı
local.indexed.atPubMed
local.indexed.atWOS
local.indexed.atScopus

Files

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: